Longitudinal association of preference-weighted health-related quality of life measures and substance use disorder outcomes

Jeffrey M. Pyne, Shanti Tripathi, Michael French, Kathryn McCollister, Richard C. Rapp, Brenda M. Booth

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Aim To examine the construct validity of generic preference-weighted health-related quality of life measures in a sample of patients with a substance use disorder (SUD). Design Longitudinal (baseline and 6-month follow-up) data from a research study that evaluated interventions to improve linkage and engagement with SUD treatment. Setting A central intake unit that referred patients to seven SUD treatment centers in a Midwestern US metropolitan area. Participants A total of 495 individuals with a SUD. Measurements Participants completed two preference-weighted measures: the self-administered Quality of Well-Being scale (QWB-SA) and the standard gamble weighted Medical Outcomes Study SF-12 (SF-6D). They were also administered two clinical assessments: all seven domains of the Addiction Severity Index (ASI) and a symptom checklist based on the DSM-IV. Construct validity was determined via the relationships between disease-specific SUD and generic measures. Findings In unadjusted analyses, the QWB-SA and SF-6D change scores were correlated significantly with six ASI subscale change scores, but not with employment status. In adjusted repeated-measures analyses, three of seven ASI subscale scores were significant predictors of QWB-SA and 5/7 ASI subscale scores were significant predictors of SF-6D. Abstinence and problematic use at follow-up were significant predictors of QWB-SA and SF-6D. Effect sizes ranged from 0.352 to 0.400 for abstinence and -0.484 to -0.585 for problematic use. Conclusions Generic preference-weighted health-related quality of life measures show moderate to good associations with substance-use specific measures and in certain circumstances can be used in their stead. This study provides further support for the use of the Quality of Well-Being scale and Medical Outcomes Study SF-12 in clinical and economic evaluations of substance use disorder interventions.

Original languageEnglish (US)
Pages (from-to)507-515
Number of pages9
JournalAddiction
Volume106
Issue number3
DOIs
StatePublished - Mar 1 2011

    Fingerprint

Keywords

  • Cost-effectiveness analysis
  • Cost-utility analysis
  • Health-related quality of life
  • Quality of Well-Being Scale
  • SF-12
  • SF-6D
  • Substance use disorder

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Psychiatry and Mental health
  • Medicine(all)

Cite this